Investing.com - Financial Markets Worldwide

Keros Therapeutics Inc (KROS)

NASDAQ
Currency in USD
15.21
+0.30(+2.01%)
Real-time Data·
KROS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
KROS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
14.8215.22
52 wk Range
9.1272.37
Key Statistics
Edit
Prev. Close
14.91
Open
14.89
Day's Range
14.82-15.22
52 wk Range
9.12-72.37
Volume
92.24K
Average Volume (3m)
529.65K
1-Year Change
-67.17%
Book Value / Share
17.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KROS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Buy
Price Target
23.00
Upside
+51.22%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 13
Net income is expected to grow this year
Unlock InvestingPro

Keros Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Keros Therapeutics Inc Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
148
Market
United States

Compare KROS to Peers and Sector

Metrics to compare
KROS
Peers
Sector
Relationship
P/E Ratio
32.3x−1.2x−0.5x
PEG Ratio
0.30−0.050.00
Price/Book
0.9x1.7x2.6x
Price / LTM Sales
2.6x8.2x3.3x
Upside (Analyst Target)
50.9%281.3%38.7%
Fair Value Upside
Unlock27.4%5.0%Unlock

Analyst Ratings

6 Buy
5 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 23.00
(+51.22% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.76 / -1.13
Revenue / Forecast
18.17M / 4.21M
EPS Revisions
a
a
Unlock
Last 90 days

KROS Income Statement

People Also Watch

CorMedix
13.925
CRMD
-0.46%
Relay
3.54
RLAY
0.00%
Astera Labs
178.10
ALAB
-0.26%
IQVIA Holdings
186.43
IQV
-0.71%
Clear Secure
36.67
YOU
+0.84%

FAQ

What Stock Exchange Does Keros Trade On?

Keros is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Keros?

The stock symbol for Keros is "KROS."

What Is the Keros Market Cap?

As of today, Keros market cap is 611.67M.

What Is Keros's Earnings Per Share (TTM)?

The Keros EPS (TTM) is 0.47.

When Is the Next Keros Earnings Date?

Keros will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is KROS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Keros Stock Split?

Keros has split 0 times.

How Many Employees Does Keros Have?

Keros has 148 employees.

What is the current trading status of Keros (KROS)?

As of 27 Aug 2025, Keros (KROS) is trading at a price of 15.21, with a previous close of 14.91. The stock has fluctuated within a day range of 14.82 to 15.22, while its 52-week range spans from 9.12 to 72.37.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.